Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection
- 15 January 2008
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 180 (2) , 948-956
- https://doi.org/10.4049/jimmunol.180.2.948
Abstract
We have previously reported that a subunit protein vaccine based on the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein and a recombinant adeno-associated virus (rAAV)-based RBD (RBD-rAAV) vaccine could induce highly potent neutralizing Ab responses in immunized animals. In this study, systemic, mucosal, and cellular immune responses and long-term protective immunity induced by RBD-rAAV were further characterized in a BALB/c mouse model, with comparison of the i.m. and intranasal (i.n.) routes of administration. Our results demonstrated that: 1) the i.n. vaccination induced a systemic humoral immune response of comparable strength and shorter duration than the i.m. vaccination, but the local humoral immune response was much stronger; 2) the i.n. vaccination elicited stronger systemic and local specific cytotoxic T cell responses than the i.m. vaccination, as evidenced by higher prevalence of IL-2 and/or IFN-γ-producing CD3+/CD8+ T cells in both lungs and spleen; 3) the i.n. vaccination induced similar protection as the i.m. vaccination against SARS-CoV challenge in mice; 4) higher titers of mucosal IgA and serum-neutralizing Ab were associated with lower viral load and less pulmonary pathological damage, while no Ab-mediated disease enhancement effect was observed; and 5) the vaccination could provide long-term protection against SARS-CoV infection. Taken together, our findings suggest that RBD-rAAV can be further developed into a vaccine candidate for prevention of SARS and that i.n. vaccination may be the preferred route of administration due to its ability to induce SARS-CoV-specific systemic and mucosal immune responses and its better safety profile.Keywords
This publication has 71 references indexed in Scilit:
- Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivityBiochemical and Biophysical Research Communications, 2007
- Evaluation of Cellular Immune Responses in Subjects Chronically Infected with HIV Type 1AIDS Research and Human Retroviruses, 2007
- Modulation of the Unfolded Protein Response by the Severe Acute Respiratory Syndrome Coronavirus Spike ProteinJournal of Virology, 2006
- Immunization of Mice with a DNA Vaccine Based on Severe Acute Respiratory Syndrome Coronavirus Spike Protein Fragment 1Viral Immunology, 2006
- Mucosal Immunization with Surface-Displayed Severe Acute Respiratory Syndrome Coronavirus Spike Protein onLactobacillus caseiInduces Neutralizing Antibodies in MiceJournal of Virology, 2006
- Toxicological Safety Evaluation of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar Despite Differing Plasmid Backbones or Gene-InsertsToxicological Sciences, 2006
- Intranasal Vaccination with Recombinant Adeno-Associated Virus Type 5 against Human Papillomavirus Type 16 L1Journal of Virology, 2006
- Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in ratsVirus Research, 2005
- A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceNature, 2004
- Long‐term transgene expression in cardiac and skeletal muscle following fetal administration of adenoviral or adeno‐associated viral vectors in miceThe Journal of Gene Medicine, 2003